| Name | Title | Contact Details |
|---|
U.S. Figure Skating is the national governing body for figure skating in the United States, established in 1921. Based in Colorado Springs, Colorado, it is recognized by the United States Olympic & Paralympic Committee and is a member of the International Skating Union. The organization promotes figure skating through various services and programs. U.S. Figure Skating offers competitive pathways for skaters, including testing and competition opportunities that lead to World and Olympic events. The "Learn to Skate USA" program supports both recreational and competitive skaters, with over 1,000 active programs across 49 states. The organization also provides resources for member clubs and offers volunteer opportunities in roles such as judging and officiating. Additionally, it sanctions competitions and provides educational materials for coaches and skaters. The organization serves a diverse customer base, including over 750 member clubs, individual skaters, and supporters of figure skating. U.S. Figure Skating is also home to the World Figure Skating Museum and Hall of Fame, attracting thousands of visitors each year.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
A-MAX Auto Insurance is a Texas-based insurance provider founded in 2002, with its headquarters in Dallas. The company specializes in affordable insurance solutions and has rapidly expanded to operate over 200 offices across Texas. In 2022, A-MAX entered the California market by acquiring Sameday Insurance, adding 10 locations in Southern California. A-MAX offers a wide range of insurance products, including auto insurance for cars, motorcycles, boats, RVs, and commercial vehicles. They also provide property insurance for homeowners, renters, and mobile homes, along with specialized services such as SR-22 certificates, Mexico tourist insurance, surety bonds, and notary services. Additionally, A-MAX has commercial solutions, including general liability and commercial auto insurance. The company operates two subsidiaries in Texas: ALPA Auto Insurance and Preferred Coverage Insurance Agency, catering to both non-standard and commercial/personal insurance needs. A-MAX focuses on delivering flexible, customer-centric service to individual consumers and businesses.
Icreon is a leading customer experience transformation company providing organizations with digital strategy consulting, design, and engineering services at scale. Founded in 2000 and headquartered in New York with offices in London and New Delhi, Icreon specializes in serving Fortune 500 clients including industry leaders like Johnson Controls, Acrisure, Jets.com to the Major League Baseball Players Association. Fortune 500 companies, growing brands, and non-profits partner with Icreon to enable their next phase of growth through digital.
Nexus is dedicated to providing the highest quality of service in the field of utilization review. We specialize in providing physician services to the utilization review and risk management industry through accurate, independent, evidence-based results which provide a high quality outcome. Our experienced physicians and professional administrative staff consistently prove to be a leader and beacon for the medical review industry.